Strategies to help youth with HIV stay virally suppressed
Part of Immune system & allergy, Infections clinical trials.
This trial tests a strategy to help young people with HIV keep their virus levels low. It focuses on using a long-acting injectable medication combination (Cabotegravir and Rilpivirine) and requires communication with your HIV doctor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are prescribed HIV medication (ART).
- You are willing to sign consent and let your HIV provider be involved.
- You do not have certain HIV drug resistances that would make the study medicine less effective.
- You are not taking medications that interact with the study drugs.
- You are not pregnant.
- You do not have a serious mental health or medical condition that would affect participation.
- You are not planning to move away in the next year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a program that encourages positive activities (behavioral activation) can help people with HIV or on PrEP who also use substances improve their health. It focuses on those receiving long-acting injectable medications for HIV prevention or treatment.
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
This study tests ways to help young people in Uganda prevent HIV or stay healthy if they already have HIV. It offers free prevention pills or injections and care for those living with HIV.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This study looks at how long an injectable HIV treatment (cabotegravir and rilpivirine) keeps working in people whose virus is already well controlled. It aims to see the real-world experience and how long patients stay on this treatment.
This trial tests a new ultra-long-acting injectable combination of cabotegravir and rilpivirine for people with HIV who already have the virus under control. It aims to see if these shots can keep the virus suppressed with fewer doses.
Hear when a new Human Immunodeficiency Virus (HIV) Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.